Study Summary
This trial will test the safety of a new drug, SGN-B7H4V, in patients with solid tumors that have spread and are inoperable or have metastasized. The trial will also study side effects of the drug.
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Gallbladder Cancer
- Hormone Receptor-positive Breast Cancer
- Endometrial Cancer
- Peritoneal Tumors
- Non-Small Cell Lung Cancer
- Adenoid Cystic Carcinoma
- Fallopian Tube Cancer
- Bile Duct Cancer
- Triple Negative Breast Cancer
- Ovarian Tumors
Treatment Effectiveness
Study Objectives
3 Primary · 11 Secondary · Reporting Duration: Up to approximately 3 years
Trial Safety
Awards & Highlights
Trial Design
1 Treatment Group
SGN-B7H4V
1 of 1
Experimental Treatment
400 Total Participants · 1 Treatment Group
Primary Treatment: SGN-B7H4V · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the scope of facilities participating in this research project?
"Ten clinics are offering this clinical trial, including Sarah Cannon Research Institute at HealthONE - Denver in Denver, Mayo Clinic Florida in Jacksonville, and Community Health Network in Indianapolis. Seven other medical centres have also been tapped for patient recruitment." - Anonymous Online Contributor
What are the primary objectives of this investigation?
"This study, which will be followed for up to three years, seeks to determine the number of participants who experience dose-limiting toxicities. The secondary goals include measuring progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) within a 30-37 day period after last treatment." - Anonymous Online Contributor
How many participants are actively involved in this clinical investigation?
"Affirmative. In accordance with the data hosted on clinicaltrials.gov, this study is actively recruiting patients and has been since 1/12/2022; it was last updated in November 11th 2022. 375 individuals are needed to be enrolled from 10 different sites." - Anonymous Online Contributor
What is the known risk profile of SGN-B7H4V for patients?
"Our team at Power has gauged the safety of SGN-B7H4V as a 1, reflecting its Phase 1 status. This implies that only minimal data exists to support efficacy and security protocols." - Anonymous Online Contributor
Are there any opportunities for participation in this experiment currently available?
"Affirmative. Clinicaltrials.gov records reveal that this medical trial, launched on December 1st 2022, is presently recruiting participants. The study seeks 375 volunteers across 10 distinct clinical sites." - Anonymous Online Contributor